A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2343954
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
创建时间：
2020-07-15
